Karl W., German histologist, 1860-1945. See: Hürthle cell, Hürthle cell adenoma, Hürthle cell carcinoma.
References in periodicals archive ?
The "benign call" rate among Hurthle cells a common but difficult-to-diagnose thyroid nodule subtype was also significantly higher using the Afirma GSC (88.8% vs.
[2] Warthin like variant can be mistaken for a lymphoepithelial lesion, Hurthle cell tumour or a tall cell variant both on cytology and histopathology.
Among patients with malignant results, detected histopathological types were papillary carcinoma in 106 patients, Hurthle cell carcinoma in 9 patients, follicular carcinoma in 6 patients, medullary carcinoma in 2 patients, poorly differentiated carcinoma in 2 patients, and anaplastic carcinoma in 1 patient.
(2,3,5,12) Interestingly, in comparison with other primaries, these tumors have been reported to be the most frequently associated with diagnostic pitfalls on FNAC, as their cytologic features commonly overlap with those of a Hurthle cell neoplasm or even macrophages.
Characteristics of study subjects Age (mean [+ or -] SD) 45.88[+ or -]13.59 Gender n (%) Male 51 (24.8%) Female 155 (75.2%) Pathology n (%) 180 (87.4%) Papillary 10 (4.9%) Follicular 7 (3.4%) Hurthle cell 9 (4.4) Poorly differentiated Tumor size mm 12 (0.5-100) (median/min-max) Metastasis localization 63 (76%) Lymph node 10 (12%) Cervical 5 (6%) Mediastinal 1 (1.2%) Cervical + 4 (4.8%) mediastinal Submental 13 (56.5%) Supraclavicular 7 (30.5%) Distant metastasis 3 (13%) Lung Bone Multiple organ metastasis Tg (ng/mL) 7.32 (0.1-30000) (median/min-max) TSH (IU/mL) 75 (23-150) (median/min-max) 0.093 (0.001-41.74) Tg/TSH (median/ min-max) SD: Standard deviation, Tg: Thyroglobulin, TSH: Thyroid-stimulating hormone, Min: Minimum, Max: Maximum Table 2.
Hurthle cell carcinoma (HCC) is a rare thyroid tumour described for the first time by Ewing in 1928.
The RNA sequencing-based Afirma GSC demonstrated especially strong performance in distinguishing benign from cancerous Hurthle cells - a category of thyroid cell that has historically been challenging to diagnose by cytopathology or molecular methods.
Hurthle cell neoplasms (HCNs) include Hurthle cell carcinoma (HCC) which accounts for 5-10% of thyroid malignancies.
The third patient with endometrial cancer had no malignancy in her axillary lymph node biopsy, but had Hurthle cell neoplasia in a thyroid biopsy; she refused surgical or medical treatment for endometrial cancer and died 23 months later.
Half of the patients had preoperative thyroid fine needle aspiration with diagnosis of 3 malignant cytology, 2 Hurthle cell neoplasia and 1 follicular neoplasia.
National Institute for Health and Clinical Excellence (NICE) as a treatment for progressive, locally advanced or metastatic differentiated thyroid cancer (papillary, follicular or Hurthle cell) in adults whose disease does not respond to radioactive iodine, in NICE's Final Appraisal Determination (FAD).(1)